Key result
Intravenous nitroglycerin administered before contrast-guided axillary vein puncture significantly reduced the mean degree of venous spasm compared to control (23.0% vs. 45.5%; P=0.018).
Why the study?
Does intravenous nitroglycerin prevent venous spasm in patients undergoing contrast-guided axillary vein puncture for pacemaker or defibrillator leads implantation?
RCT (n=40)
Does intravenous nitroglycerin prevent venous spasm in patients undergoing contrast-guided axillary vein puncture for pacemaker or defibrillator leads implantation?
Absolute Event Rate: 23% vs 45.5%
p-value: p=0.018
Intravenous nitroglycerin (200 µg) administered prior to contrast-guided axillary vein puncture significantly reduces the incidence and severity of venous spasm safely without causing hypotension.
Supports prophylactic IV nitroglycerin for axillary access in CIED implantation; confirms spasm reduction in this RCT.
AIMS: We investigated the efficacy and safety of nitroglycerin for preventing venous spasm during contrast-guided axillary vein puncture for pacemaker or defibrillator leads implantation. METHODS AND RESULTS: A total of 40 consecutive patients referred for contrast-guided axillary vein puncture for pacemaker or defibrillator implantations were included in the study. Patients were randomly assigned to control group and nitroglycerin group. Patients in the nitroglycerin group were given 200 µg (2 mL) nitroglycerin via ipsilateral peripheral vein about 3 min before puncture. The degree of venous spasm was evaluated by the reduction in lumen calibre of the axillary vein after puncture. Mild venous spasm and severe venous spasm were defined as a reduction in lumen calibre of 50-90% and ≥ 90%, respectively. The mean degree of venous spasm of axillary vein was lower in the nitroglycerin group than in the control group (23.0 ± 22.3 vs. 45.5 ± 33.6%, P = 0.018). The incidence of mild or severe venous spasm was lower in the nitroglycerin group than in the control group (3/20 vs. 11/20, P = 0.019). In the nitroglycerin group, the systolic blood pressure had a significant decrease after puncture (129.5 ± 23.7 vs. 143.0 ± 24.1 mmHg, P = 0.003). There was no hypotension and other adverse reaction of nitroglycerin in the nitroglycerin group. CONCLUSION: Intravenous nitroglycerin is effective and safe for preventing venous spasm during contrast-guided axillary vein puncture for pacemaker or defibrillator leads implantation.
No takes yet. Share an insight, caveat, or question.
Duan et al. (2012) conducted an RCT in Patients referred for contrast-guided axillary vein puncture for pacemaker or defibrillator implantations (n=40). Nitroglycerin vs. Control group was evaluated on Mean degree of venous spasm evaluated by the reduction in lumen calibre of the axillary vein after puncture (p=0.018). Intravenous nitroglycerin administered before contrast-guided axillary vein puncture significantly reduced the mean degree of venous spasm compared to control (23.0% vs. 45.5%; P=0.018).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: